Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Farmaforce
Latest News
Biosim education to be unaccredited
Biosimilars: After cancelling a call for accreditation tenders, the Health Department says it will publish unaccredited biosim awareness education materials while it decides what to do next.
TGA slams AFR on cannabis story
Media: The TGA has published a lengthy and detailed rebuttal of an Australian Financial Review story on 'Australia's largest medicinal cannabis grower'.
Trump reaffirms drug price pressure
Pricing: The US President-elect reiterates his intention to push for the reduction of US pharma prices, sending pharma and biotech stocks into a tailspin.
Baxter, MSD recognised for gender equity
Workplace: MSD and Baxter Healthcare have been named as Employers of Choice for their gender equity achievements for the second consecutive year.
Pfizer fined record amount in UK
Price Regulation: Pfizer and its UK distributor hit with record fine by British watchdog after 2600 per cent drug price hike - but the company says it will appeal.
Most Popular
Roche, Pharmac in biggest-ever deal
Reimbursement: NZ's Pharmac nails biggest deal in its history with a multiple Roche drug package for cancer, respiratory, rheumatology and other diseases.
Big 2017 looming for PBAC
Reimbursement: More than sixty notable TGA approvals took place in 2016. Many can be expected move on to the PBAC this year, not to mention a potential flood of resubmissions from 2016 rejections. Pharma in Focus identifies the top candidates and markets.
Greens take a swipe at pharma
Reputation: Greens Senator Sarah Hanson-Young lets fly at pharma over US trade negotiation tactics.
Chemist Warehouse forced to pay back millions
Retail: The massive pharmacy discounter enters compliance partnership with Fair Work Ombudsman after underpayment scandal sees backpay going to two-thirds of its workforce.
Patent expiries hit markets worth $100m today
Generics: Generics will list against originator brands for drugs currently worth $100 million in R/PBS benefits today, affecting a number of major companies.
Earlier
Aust pharma growth forecast to halve
Industry: A new set of global pharma growth predictions from QuintilesIMS expects Australia's growth to halve over the next five years.
Key plank of biosim awareness dumped
Biosimilars: Health Minister Sussan Ley's office feared CPD-based option would have the opposite of its intended effect and it was cancelled.
Pharma's political donations compared
Reputation: Mining of the Green's political donations database shows pharma/health was the fifth most generous industry sector during the 2013 election year.
Govt's wish list for therapeutics research
Innovation: National Research Infrastructure Roadmap highlights 'significant gaps' around Australia's ability to develop therapies from research.
GSK backs female start-ups
Innovation: GSK Australia has announced it will support 'SheStarts', a national accelerator program 'to turbocharge female leadership in the startup economy'.
Pipeline Monitor
Avastin scores ninth approval
Roche's Avastin scores its ninth approval across six cancer types while a once-weekly diabetes treatment and a triple COPD therapy are filed.
Debating Point
Biosimilars - a promise delayed by bureaucracy
It's a year since Pfizer's Inflectra was PBS listed but the promised biosimilar awareness initiative is nowhere to be seen.
Approvals Action
Samsung Bioepis continues to emerge in biosimilars
The emergence of Samsung Bioepis as an important sponsor of biosimilars in Australia has continued with the registration of Renflexis, a version of infliximab.
FREE Content
Events & Conferences
SEARCH NOW
Pharma in Focus Jobs
Ascott Sales